Compare NWPX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWPX | EYPT |
|---|---|---|
| Founded | 1966 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1996 | 2005 |
| Metric | NWPX | EYPT |
|---|---|---|
| Price | $113.88 | $13.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $70.00 | $31.80 |
| AVG Volume (30 Days) | 190.5K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.71 | N/A |
| EPS | ★ 2.69 | N/A |
| Revenue | ★ $526,003,000.00 | $7,539,000.00 |
| Revenue This Year | $6.98 | N/A |
| Revenue Next Year | $3.30 | $3,115.57 |
| P/E Ratio | $41.55 | ★ N/A |
| Revenue Growth | ★ 6.79 | N/A |
| 52 Week Low | $49.45 | $9.65 |
| 52 Week High | $152.03 | $19.11 |
| Indicator | NWPX | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 33.96 | 55.33 |
| Support Level | $105.00 | $13.17 |
| Resistance Level | $114.27 | $15.01 |
| Average True Range (ATR) | 6.81 | 0.88 |
| MACD | -1.74 | 0.15 |
| Stochastic Oscillator | 11.04 | 76.26 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products, and operates in two segments, Water Transmission Systems (WTS), operating as the Northwest Pipe Company brand, and Precast Infrastructure and Engineered Systems (Precast), which includes the brands NWPX Geneva and NWPX Park. WTS manufactures large-diameter, high-pressure steel pipeline systems for use in water infrastructure applications, which are related to drinking water systems. Precast manufactures stormwater and wastewater technology products, high-quality precast and reinforced concrete products, including reinforced concrete pipe (RCP), manholes, box culverts, vaults, and catch basins, pump lift stations, oil water separators, biofiltration units, and other environmental and engineered solutions.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.